Jorge E Buendia-Buendia
Harvard University
H-index: 8
North America-United States
Top articles of Jorge E Buendia-Buendia
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial
Nature Communications
2024/3/19
The Metastatic Breast Cancer Project: leveraging patient-partnered research to expand the clinical and genomic landscape of metastatic breast cancer and accelerate discoveries
medRxiv
2023
Abstract P4-01-06: Genomic and transcriptomic analysis reveals known and novel resistance mechanisms to CDK4/6 inhibitors and sensitivity factors for the response to triplet …
Cancer Research
2022/2/15
Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic …
2022/7/12
A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women …
Breast Cancer Research and Treatment
2021/9
Tianyu Li
H-Index: 0
Nabihah Tayob
H-Index: 13
Esha Jain
H-Index: 9
Jorge E Buendia-Buendia
H-Index: 6
Nikhil Wagle
H-Index: 42
Abstract OT-18-01: The metastatic breast cancer project: Generating the clinical and genomic landscape of metastatic breast cancer through patient-partnered research
Cancer Research
2021/2/15
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma
Nature medicine
2021/2
Abstract PO-015: The Metastatic Breast Cancer Project in Spanish: Developing a Spanish language patient-partnered research project with the Latinx community through culturally …
Cancer Epidemiology, Biomarkers & Prevention
2020/12/1
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
Clinical Cancer Research
2020/11/15
Ofir Cohen
H-Index: 21
Jorge E Buendia-Buendia
H-Index: 6
Utthara Nayar
H-Index: 5
Samuel Freeman
H-Index: 20
Nikhil Wagle
H-Index: 42
Abstract B23: Genomic sequencing of metastatic hormone-receptor positive breast cancer implicates AKT1 in driving resistance to cyclin-dependent kinase 4/6 inhibitors
Molecular Cancer Research
2020/10/1
The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor–positive metastatic breast cancer
Cancer discovery
2020/8/1
Ofir Cohen
H-Index: 21
Jorge E Buendia-Buendia
H-Index: 6
Utthara Nayar
H-Index: 5
Ricardo Martinez
H-Index: 0
Gerald Batist
H-Index: 32
Nikhil Wagle
H-Index: 42
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
Annals of Oncology
2020/5/1
Prevalence and mutational determinants of high tumor mutation burden in breast cancer
Annals of Oncology
2020/3/1
Abstract P3-01-09: Clonal heterogeneity and tumor evolution inform treatment resistance in a patient with HER2+ breast cancer
Cancer Research
2020/2/15
Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+ …
Cancer Research
2020/2/15
